Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Gemfibrozil (CI-719) 是一种PPAR-α激活剂,可作为降脂药。它也是P450非选择性抑制剂,对 CYP2C9、2C19、2C8 和 1A2 的Ki 值分别为 5.8、24、69 和 82 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 170 | 现货 | ||
50 mg | ¥ 252 | 现货 | ||
100 mg | ¥ 327 | 现货 | ||
200 mg | ¥ 458 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 415 | 现货 |
产品描述 | Gemfibrozil (CI-719) interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. Gemfibrozil is a fibric acid derivative with hypolipidemic effects. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III result in the subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C). |
靶点活性 | CYP2C9:5.8 μM(Ki), 2C19:24 μM(Ki), 1A2:82 μM(Ki), 2C8:69 μM(Ki) |
体外活性 | Gemfibrozil exerts a minimal inhibitory effect on CYP3A-mediated simvastatin hydroxy acid (SVA) oxidation, but does inhibit SVA glucuronidation in dog and human liver microsomes. [1] Gemfibrozil markedly inhibits M-23 formation, with a K(i) (IC(50)) value of 69 (95) mM, whereas inhibition of M-1 formation is weaker with a K(i) (IC(50)) value of 273 mM in human liver microsomes. [2] Gemfibrozil strongly and competitively inhibits CYP2C9 activity, with a K(i) (IC(50)) value of 5.8 (9.6) mM. Gemfibrozil exhibits somewhat smaller inhibitory effects on CYP2C19 and CYP1A2 activities, with K(i) (IC(50)) values of 24 (47) mM and 82 (136) mM, respectively. [3] Gemfibrozil, a lipid-lowering drug, inhibits cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373 mg astroglial cells and primary astrocytes. Gemfibrozil induces peroxisome proliferator-responsive element (PPRE)-dependent luciferase activity, which is inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha. Gemfibrozil strongly inhibits the activation of NF-kappaB, AP-1, and C/EBPbeta but not that of gamma-activation site (GAS) in cytokine-stimulated astroglial cells. [4] |
体内活性 | Gemfibrozil treatment significantly reduces (2-3-fold) the plasma clearance of SVA and the biliary excretion of SVA glucuronide (together with its cyclization product SV), but not the excretion of a major oxidative metabolite of SVA in dogs. [1] |
别名 | 吉非罗齐, CI-719, Jezil, Decrelip, Lopid |
分子量 | 250.33 |
分子式 | C15H22O3 |
CAS No. | 25812-30-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 47 mg/mL (187.8 mM)
Ethanol: 47 mg/mL (187.8 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 3.9947 mL | 19.9736 mL | 39.9473 mL | 99.8682 mL |
5 mM | 0.7989 mL | 3.9947 mL | 7.9895 mL | 19.9736 mL | |
10 mM | 0.3995 mL | 1.9974 mL | 3.9947 mL | 9.9868 mL | |
20 mM | 0.1997 mL | 0.9987 mL | 1.9974 mL | 4.9934 mL | |
50 mM | 0.0799 mL | 0.3995 mL | 0.7989 mL | 1.9974 mL | |
100 mM | 0.0399 mL | 0.1997 mL | 0.3995 mL | 0.9987 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Gemfibrozil 25812-30-0 DNA Damage/DNA Repair GPCR/G Protein Metabolism Neuroscience P450 Adrenergic Receptor PPAR Peroxisome proliferator-activated receptors Inhibitor inhibit 吉非罗齐 CI719 CI 719 Cytochrome P450 CYPs CI-719 Jezil Decrelip Lopid inhibitor